JP2010504743A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010504743A5 JP2010504743A5 JP2009529701A JP2009529701A JP2010504743A5 JP 2010504743 A5 JP2010504743 A5 JP 2010504743A5 JP 2009529701 A JP2009529701 A JP 2009529701A JP 2009529701 A JP2009529701 A JP 2009529701A JP 2010504743 A5 JP2010504743 A5 JP 2010504743A5
- Authority
- JP
- Japan
- Prior art keywords
- tumor
- antibody
- resistant
- functional fragments
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010028980 Neoplasm Diseases 0.000 claims 54
- 238000000034 method Methods 0.000 claims 32
- 239000012634 fragment Substances 0.000 claims 29
- 150000001875 compounds Chemical class 0.000 claims 25
- 230000000259 anti-tumor effect Effects 0.000 claims 23
- 241001465754 Metazoa Species 0.000 claims 13
- 239000000427 antigen Substances 0.000 claims 10
- 102000036639 antigens Human genes 0.000 claims 10
- 108091007433 antigens Proteins 0.000 claims 10
- 239000003814 drug Substances 0.000 claims 8
- 102000039446 nucleic acids Human genes 0.000 claims 8
- 108020004707 nucleic acids Proteins 0.000 claims 8
- 150000007523 nucleic acids Chemical class 0.000 claims 8
- 210000004408 hybridoma Anatomy 0.000 claims 6
- 238000000338 in vitro Methods 0.000 claims 6
- 210000004881 tumor cell Anatomy 0.000 claims 6
- 239000013592 cell lysate Substances 0.000 claims 5
- 229940079593 drug Drugs 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 4
- 239000000725 suspension Substances 0.000 claims 4
- 230000001225 therapeutic effect Effects 0.000 claims 4
- 239000002246 antineoplastic agent Substances 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 210000004027 cell Anatomy 0.000 claims 3
- 230000002401 inhibitory effect Effects 0.000 claims 3
- 102000004169 proteins and genes Human genes 0.000 claims 3
- 108090000623 proteins and genes Proteins 0.000 claims 3
- 241001529936 Murinae Species 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 206010070834 Sensitisation Diseases 0.000 claims 2
- 238000001574 biopsy Methods 0.000 claims 2
- 229940044683 chemotherapy drug Drugs 0.000 claims 2
- 239000001963 growth medium Substances 0.000 claims 2
- 238000001794 hormone therapy Methods 0.000 claims 2
- 230000006698 induction Effects 0.000 claims 2
- 238000002347 injection Methods 0.000 claims 2
- 239000007924 injection Substances 0.000 claims 2
- 230000010534 mechanism of action Effects 0.000 claims 2
- 239000002773 nucleotide Substances 0.000 claims 2
- 125000003729 nucleotide group Chemical group 0.000 claims 2
- 238000001959 radiotherapy Methods 0.000 claims 2
- 238000012216 screening Methods 0.000 claims 2
- 230000008313 sensitization Effects 0.000 claims 2
- 230000001235 sensitizing effect Effects 0.000 claims 2
- 241000894007 species Species 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- 238000001356 surgical procedure Methods 0.000 claims 2
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 claims 2
- 239000005483 tyrosine kinase inhibitor Substances 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 102000019034 Chemokines Human genes 0.000 claims 1
- 108010012236 Chemokines Proteins 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 102000009465 Growth Factor Receptors Human genes 0.000 claims 1
- 108010009202 Growth Factor Receptors Proteins 0.000 claims 1
- 108060003951 Immunoglobulin Proteins 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 102000001708 Protein Isoforms Human genes 0.000 claims 1
- 108010029485 Protein Isoforms Proteins 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 230000033115 angiogenesis Effects 0.000 claims 1
- 210000003719 b-lymphocyte Anatomy 0.000 claims 1
- 210000000481 breast Anatomy 0.000 claims 1
- 230000012292 cell migration Effects 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 210000001072 colon Anatomy 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 230000000295 complement effect Effects 0.000 claims 1
- 210000004748 cultured cell Anatomy 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 238000009792 diffusion process Methods 0.000 claims 1
- 102000018358 immunoglobulin Human genes 0.000 claims 1
- 239000003018 immunosuppressive agent Substances 0.000 claims 1
- 229940125721 immunosuppressive agent Drugs 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 102000006495 integrins Human genes 0.000 claims 1
- 108010044426 integrins Proteins 0.000 claims 1
- 239000007928 intraperitoneal injection Substances 0.000 claims 1
- 238000010253 intravenous injection Methods 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 244000005700 microbiome Species 0.000 claims 1
- 201000000050 myeloid neoplasm Diseases 0.000 claims 1
- LWGJTAZLEJHCPA-UHFFFAOYSA-N n-(2-chloroethyl)-n-nitrosomorpholine-4-carboxamide Chemical compound ClCCN(N=O)C(=O)N1CCOCC1 LWGJTAZLEJHCPA-UHFFFAOYSA-N 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- 230000003439 radiotherapeutic effect Effects 0.000 claims 1
- 230000004044 response Effects 0.000 claims 1
- 230000003248 secreting effect Effects 0.000 claims 1
- 210000004989 spleen cell Anatomy 0.000 claims 1
- 238000010254 subcutaneous injection Methods 0.000 claims 1
- 239000007929 subcutaneous injection Substances 0.000 claims 1
- 230000008685 targeting Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0608514A FR2906533B1 (fr) | 2006-09-28 | 2006-09-28 | Procede de generation d'anticorps actifs contre un antigene de resistance,anticorps obtenus par ledit procede et leurs utilisations |
| FR06/08514 | 2006-09-28 | ||
| PCT/EP2007/060243 WO2008046724A1 (en) | 2006-09-28 | 2007-09-27 | Method for generating active antibodies against a resistance antigen, antibodies obtained by said method and their uses |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010504743A JP2010504743A (ja) | 2010-02-18 |
| JP2010504743A5 true JP2010504743A5 (enExample) | 2010-11-25 |
| JP5774276B2 JP5774276B2 (ja) | 2015-09-09 |
Family
ID=38164542
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009529701A Expired - Fee Related JP5774276B2 (ja) | 2006-09-28 | 2007-09-27 | 耐性抗原に対する活性抗体を作製する方法、その方法により得られる抗体およびそれらの使用 |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US8241646B2 (enExample) |
| EP (4) | EP2491945B9 (enExample) |
| JP (1) | JP5774276B2 (enExample) |
| KR (1) | KR101504770B1 (enExample) |
| CN (1) | CN101516394B (enExample) |
| AR (1) | AR063061A1 (enExample) |
| AU (1) | AU2007312437C1 (enExample) |
| BR (1) | BRPI0717246A2 (enExample) |
| CA (1) | CA2663561A1 (enExample) |
| FR (1) | FR2906533B1 (enExample) |
| IL (1) | IL197790A (enExample) |
| MA (1) | MA30954B1 (enExample) |
| MX (1) | MX2009003245A (enExample) |
| NO (1) | NO20091613L (enExample) |
| NZ (1) | NZ576420A (enExample) |
| RU (1) | RU2515904C2 (enExample) |
| TN (1) | TN2009000102A1 (enExample) |
| TW (1) | TWI516276B (enExample) |
| UA (1) | UA102812C2 (enExample) |
| WO (1) | WO2008046724A1 (enExample) |
| ZA (1) | ZA200902697B (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7241444B2 (en) * | 2002-01-18 | 2007-07-10 | Pierre Fabre Medicament | Anti-IGF-IR antibodies and uses thereof |
| CU23736A1 (es) * | 2009-05-04 | 2011-11-15 | Centro Inmunologia Molecular | Anticuerpos que reconocen sulfatidos y proteoglicanos sulfatados y su uso |
| WO2011004899A1 (en) * | 2009-07-06 | 2011-01-13 | Takeda Pharmaceutical Company Limited | Cancerous disease modifying antibodies |
| US20120282211A1 (en) * | 2009-11-24 | 2012-11-08 | Carnegie Mellon University | Antibodies and conjugates for modulators of angiogenesis |
| EP3165538A1 (en) | 2010-11-03 | 2017-05-10 | Argen-X Nv | Anti c-met antibodies |
| US9255595B2 (en) * | 2011-04-29 | 2016-02-09 | Bae Systems Information And Electronic Systems Integration Inc. | Optical dome bezel |
| EP2773660A2 (en) | 2011-11-03 | 2014-09-10 | Argen-X B.V. | Chimeric human-camel antigens and their use |
| BR112015022123B1 (pt) * | 2013-03-15 | 2022-08-09 | Intrinsic Lifesciences, Llc | Anticorpos, fragmentos de ligação ao antígeno dos mesmos que se ligam especificamente à hepcidina ou um peptídeo de hepcidina, uso, meio contentor e kit |
| CN106794194A (zh) * | 2014-06-30 | 2017-05-31 | 中央研究院 | 用于癌症治疗的介白素‑17受体b（il‑17rb）及其配体il‑17b之拮抗剂 |
| AU2015321462B2 (en) | 2014-09-22 | 2020-04-30 | Intrinsic Lifesciences Llc | Humanized anti-hepcidin antibodies and uses thereof |
| TWI716400B (zh) * | 2015-04-27 | 2021-01-21 | 法商皮爾法伯製藥公司 | 新穎的igf-1r抗體及其用於癌症診斷之用途（二） |
| AR104413A1 (es) * | 2015-04-27 | 2017-07-19 | Pf Medicament | Anticuerpo de igf-1r y su utilización para diagnosticar cáncer |
| JP6976241B2 (ja) * | 2015-08-14 | 2021-12-08 | メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. | 抗ｔｉｇｉｔ抗体 |
| JP6952028B2 (ja) * | 2015-09-29 | 2021-10-20 | シャンハイ チャンジアン バイオテクノロジー カンパニー リミテッド | Ｐｄ−１抗体およびその使用 |
| GB2547179A (en) * | 2015-10-26 | 2017-08-16 | Quethera Ltd | Genetic construct |
| WO2025111382A2 (en) * | 2023-11-21 | 2025-05-30 | Board Of Regents, The University Of Texas System | Anti-lamp5 antibodies, engineered immune cells expressing anti-lamp5 antibodies, and uses thereof |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| JPS6261596A (ja) * | 1985-09-11 | 1987-03-18 | Japan Found Cancer Res | 薬剤耐性癌に関するモノクロ−ナル抗体およびその製造 |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| GB8924581D0 (en) | 1989-11-01 | 1989-12-20 | Pa Consulting Services | Bleaching of hair |
| ATE356869T1 (de) | 1990-01-12 | 2007-04-15 | Amgen Fremont Inc | Bildung von xenogenen antikörpern |
| GB9014932D0 (en) | 1990-07-05 | 1990-08-22 | Celltech Ltd | Recombinant dna product and method |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| JPH05244982A (ja) | 1991-12-06 | 1993-09-24 | Sumitomo Chem Co Ltd | 擬人化ｂ−ｂ１０ |
| KR950700061A (ko) * | 1992-02-06 | 1995-01-16 | 스티븐 엘. 네스비트 | 테트라아릴에틸렌에 의한 다중 약물 내성의 역전(reversal of multi -drug resistance by tetraarylethylenes) |
| IT1257893B (it) * | 1992-06-17 | 1996-02-16 | Ist Superiore Sanita | Anticorpi monoclonali che riconoscono un epitopo della p-glicoproteina umana. |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| US5503984A (en) * | 1993-04-13 | 1996-04-02 | Health Research, Inc. | Hybridoma producing monoclonal antibody F4 which specifically binds to multidrug resistant P-glycoprotein and assays for detection of P-glycoprotein |
| WO1999066027A1 (en) * | 1998-06-15 | 1999-12-23 | The Research Foundation Of State University Of New York | Monoclonal antibodies that recognize antigens associated with tumor metastasis |
| US7303760B2 (en) | 1999-04-23 | 2007-12-04 | Alza Corporation | Method for treating multi-drug resistant tumors |
| EP1806364B1 (fr) | 2002-01-18 | 2013-07-31 | Pierre Fabre Medicament | Nouveaux anticorps anti-igf-ir et leurs applications |
| WO2004026293A2 (en) | 2002-09-20 | 2004-04-01 | Wyeth Holdings Corporation | Hemiasterlin derivatives for treating resistant tumors |
| US20050142609A1 (en) * | 2003-10-08 | 2005-06-30 | Ebioscience | Native immunoglobulin binding reagents and methods for making and using same |
| PT1720540E (pt) | 2004-02-18 | 2008-09-10 | Gpc Biotech Ag | Métodos de tratamento de tumores resistentes ou refractários |
| EP1742060A1 (en) * | 2005-01-24 | 2007-01-10 | DIGILAB BioVisioN GmbH | TIF1-beta peptides and nucleic acids for diagnosis and therapy of cancer and colorectal cancerous disorders. |
-
2006
- 2006-09-28 FR FR0608514A patent/FR2906533B1/fr not_active Expired - Fee Related
-
2007
- 2007-09-27 MX MX2009003245A patent/MX2009003245A/es active IP Right Grant
- 2007-09-27 NZ NZ576420A patent/NZ576420A/en not_active IP Right Cessation
- 2007-09-27 CN CN200780035523.8A patent/CN101516394B/zh not_active Expired - Fee Related
- 2007-09-27 EP EP12159083.0A patent/EP2491945B9/en active Active
- 2007-09-27 EP EP07820636.4A patent/EP2081592B1/en active Active
- 2007-09-27 CA CA002663561A patent/CA2663561A1/en not_active Abandoned
- 2007-09-27 KR KR1020097008469A patent/KR101504770B1/ko not_active Expired - Fee Related
- 2007-09-27 WO PCT/EP2007/060243 patent/WO2008046724A1/en not_active Ceased
- 2007-09-27 EP EP12159077.2A patent/EP2494984B1/en active Active
- 2007-09-27 RU RU2009114682/10A patent/RU2515904C2/ru not_active IP Right Cessation
- 2007-09-27 BR BRPI0717246-0A2A patent/BRPI0717246A2/pt not_active IP Right Cessation
- 2007-09-27 JP JP2009529701A patent/JP5774276B2/ja not_active Expired - Fee Related
- 2007-09-27 EP EP12159086.3A patent/EP2497491B1/en active Active
- 2007-09-27 UA UAA200904020A patent/UA102812C2/ru unknown
- 2007-09-27 AU AU2007312437A patent/AU2007312437C1/en not_active Ceased
- 2007-09-27 US US12/442,918 patent/US8241646B2/en not_active Expired - Fee Related
- 2007-09-28 TW TW096136193A patent/TWI516276B/zh not_active IP Right Cessation
- 2007-09-28 AR ARP070104320A patent/AR063061A1/es unknown
-
2009
- 2009-03-24 IL IL197790A patent/IL197790A/en not_active IP Right Cessation
- 2009-03-26 TN TN2009000102A patent/TN2009000102A1/fr unknown
- 2009-04-17 MA MA31800A patent/MA30954B1/fr unknown
- 2009-04-20 ZA ZA200902697A patent/ZA200902697B/xx unknown
- 2009-04-22 NO NO20091613A patent/NO20091613L/no not_active Application Discontinuation
-
2012
- 2012-07-09 US US13/544,672 patent/US8808667B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010504743A5 (enExample) | ||
| CN106967172B (zh) | 抗ctla4-抗pd-1 双功能抗体、其药物组合物及其用途 | |
| JP5774276B2 (ja) | 耐性抗原に対する活性抗体を作製する方法、その方法により得られる抗体およびそれらの使用 | |
| US20090297509A1 (en) | Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases | |
| CN116731179A (zh) | 抗ror1抗体及其制备和使用方法 | |
| HK1040720A1 (zh) | 用辐射和生长因子受体酪氨酸激酶抑制剂治疗人肿瘤 | |
| RU2451689C2 (ru) | Новые антипролиферативные антитела | |
| Davis et al. | Transgenic mice as a source of fully human antibodies for the treatment of cancer | |
| WO2017197667A1 (zh) | 抗人pd-l1人源化单克隆抗体及其应用 | |
| CN102702358A (zh) | 针对csf-1r的抗体 | |
| CN112500485B (zh) | 一种抗b7-h3抗体及其应用 | |
| CN101970497A (zh) | 抗-EpCAM抗体及其用途 | |
| JP2010509931A5 (enExample) | ||
| CN103833852A (zh) | 针对磷脂酰肌醇蛋白多糖-3和t细胞抗原的双特异性抗体 | |
| CN102321173A (zh) | 人源化巨噬细胞抑制因子1单克隆抗体及其应用 | |
| CN110894241B (zh) | 一种靶向抗原特异性t细胞诱导其向记忆干性细胞分化的融合蛋白 | |
| CN115038718A (zh) | 抗人程序性死亡配体-1（pd-l1）的抗体及其用途 | |
| US20240358759A1 (en) | Combination cancer therapy with memory nk cells and anti-cancer bispecific molecules | |
| CN111094339A (zh) | 抗pd-1抗体和抗lag-3抗体联合在制备治疗肿瘤的药物中的用途 | |
| EP1810980A1 (en) | Interleukin-6 inhibitors | |
| WO2022037002A1 (zh) | 特异性结合糖基化ceacam5的抗体 | |
| CN115850475B (zh) | 人源化抗人ctla4单克隆抗体及其制备方法和用途 | |
| CN114616245A (zh) | 一种抗cd38的抗体及其用途 | |
| CN106963950B (zh) | 用于治疗肿瘤的联合用药物 | |
| TWI816616B (zh) | 抗人程序性死亡配體-1 (pd-l1) 的抗體及其用途 |